Bactericidal effect of pyridine-2-thiol 1-oxide sodium salt and its complex with iron against resistant clinical isolates of Mycobacterium tuberculosis

Autor(es)

Campos, Debora L. ^[1] ; Machado, Ignacio ^[2] ; Ribeiro, Camila M. ^[1] ; Gambino, Dinorah ^[3] ; Pavan, Fernando R. ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Fac Pharmaceut Sci, Dept Biol Sci, Araraquara, SP - Brazil

^[2] Univ Republica, Fac Quim, Area Quim Analit, Montevideo - Uruguay

^[3] Univ Republica, Fac Quim, Area Quim Inorgan, Montevideo - Uruguay

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF ANTIBIOTICS; v. 73, n. 2, p. 120-124, FEB 2020.
• Citações Web of Science: 1

Resumo

The objective of this study was to determine the activity of pyridine-2-thiol 1-oxide sodium salt (Na mpo) and its complex with iron {[}Fe(mpo)(3)] against Mycobacterium tuberculosis. The compounds were tested against a standard strain of M. tuberculosis H(37)Rv (ATCC 27294), with minimal inhibitory concentrations (MIC90) of 7.20 and 1.07 mu M to Na mpo and {[}Fe(mpo)(3)], respectively, and against three clinical isolates with different genotypic profiles, with MIC values ranging from 0.74 to 6.52 and 0.30 to 2.25 mu M to Na mpo and {[}Fe(mpo)(3)], respectively. {[}Fe(mpo)(3)] was more effective against susceptible strains but both compounds were effective in inhibiting MDR and XDR-TB clinical strains. The profile activity was determined through the methodology of a time-kill curve against standard and clinical strains of M. tuberculosis. Time-kill studies indicated that Na mpo had an early bactericidal activity against H(37)Rv and clinical isolates, with sterilizing effects observed in 5 and 7 days, respectively, at its MIC90. The anti MDR and XDR-M. tuberculosis activity and bactericidal effect of Na mpo and {[}Fe(mpo)(3)] demonstrate their potential as new compounds for the treatment of tuberculosis. (AU)

• Processo FAPESP: 18/00163-0 - Desenvolvimento e busca de novos antimicrobianos contra Tuberculose: da triagem a estudos pré-clínicos in vivo
• Beneficiário: Fernando Rogério Pavan
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/14957-5 - Investigação do potencial contra tuberculose de uma nova classe de compostos furoxânicos e compostos nanoestruturados de rutênio(II) e cobre(II)
• Beneficiário: Fernando Rogério Pavan
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores